Librela is not a steroid. It is a monoclonal antibody, a type of biologic therapy that works completely differently from steroids like prednisone or dexamethasone. The FDA approved Librela (bedinvetmab) in May 2023 as the first monoclonal antibody for dogs, specifically for controlling pain associated with osteoarthritis.
What Librela Actually Is
Monoclonal antibodies are lab-engineered proteins designed to target one specific molecule in the body. In Librela’s case, that target is nerve growth factor, or NGF, a protein that plays a major role in chronic pain signaling. When NGF levels rise around arthritic joints, it activates sensory nerve pathways that amplify pain. Librela binds to NGF and neutralizes it before it can trigger those pain signals.
This is fundamentally different from how steroids work. Corticosteroids suppress the immune system broadly, dialing down inflammation throughout the entire body. That wide-reaching effect is why steroids carry a long list of side effects in dogs, including increased thirst and urination, weight gain, muscle wasting, elevated blood sugar, and increased risk of serious gastrointestinal ulceration with long-term use. Librela’s approach is far more targeted: it blocks one specific pain-related protein rather than suppressing the whole inflammatory system.
How Librela Is Given
Your vet administers Librela as a subcutaneous injection (just under the skin) once a month. The dose is based on your dog’s weight, with a minimum target of 0.5 mg per kilogram. Dogs weighing 11 pounds or more receive the full contents of one or two pre-measured vials matched to their weight range. Smaller dogs under 11 pounds get a precise volume drawn from a vial based on their exact weight.
Because it’s a monthly injection given at the vet’s office, there are no pills to manage at home and no concern about missed daily doses.
How It Compares to Other Pain Treatments
Before Librela, the main pharmaceutical options for canine osteoarthritis pain were NSAIDs (non-steroidal anti-inflammatory drugs) like carprofen, meloxicam, and grapiprant. Corticosteroids were sometimes used but generally avoided for long-term arthritis management because of their cumulative side effects. Librela opened a new category entirely.
That said, Librela is not without risks of its own. A large-scale pharmacovigilance review covering over 18 million doses sold worldwide between February 2021 and June 2024 found that adverse events were rare, occurring at a rate of about 9.5 events per 10,000 treated animals. The most frequently reported issue was simply that the drug didn’t seem to work for a particular dog, at a rate of 1.7 per 10,000 doses. Other rare reports included increased thirst, coordination problems, increased urination, loss of appetite, lethargy, and vomiting.
One area of concern that has drawn attention involves musculoskeletal problems. Because NGF also plays a role in maintaining bone and cartilage health, blocking it may affect joint integrity over time. A study examining adverse event reports found that ligament and tendon injuries, joint inflammation, fractures, and septic arthritis were reported roughly nine times more frequently in Librela-treated dogs than in dogs treated with NSAID alternatives. An independent panel of veterinary specialists who reviewed these cases expressed strong suspicion of a causal link between Librela and the observed joint damage, though more research is ongoing. This parallels what was seen in human clinical trials of similar anti-NGF drugs years earlier.
Why People Confuse It With a Steroid
The confusion likely comes from the fact that steroids have been a go-to for managing pain and inflammation in dogs for decades, so any new injectable pain medication gets lumped into that category. Librela also happens to share one superficial similarity with steroid injections: both are given by a vet rather than taken as a daily pill at home. But the resemblance ends there.
Steroids work by broadly suppressing inflammation and immune responses. Librela does not reduce inflammation at all. It intercepts pain signals at the source by neutralizing the protein that sensitizes nerves around damaged joints. A dog on Librela still has the same level of joint inflammation it had before; the drug changes how intensely the nervous system registers that inflammation as pain. This distinction matters because it means Librela doesn’t carry the immunosuppressive risks of steroids, like increased susceptibility to infections or hormonal disruption, but it also means it isn’t treating the underlying disease process.
What to Expect if Your Dog Starts Librela
Most dogs begin showing improvement within the first week of their initial injection, though some take two or three monthly doses before the full effect becomes apparent. Because the drug is cleared from the body over the course of a month, its effects wear off gradually if you stop treatment. There’s no abrupt withdrawal period like you might see when tapering a dog off steroids.
Your vet will likely want to monitor your dog’s mobility and comfort level at follow-up visits to assess whether the drug is working. If your dog is also taking NSAIDs, your vet may discuss whether to continue both or transition to Librela alone. Some dogs do well on Librela as a standalone treatment, while others benefit from a combination approach depending on the severity of their arthritis.